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This article is featured in this month’s AJP Audio .
Gene-Environment Interactions With Cognition 
in Late Life and Compression of Morbidity
Rapid research advances in Alzheimer’s disease over the past three decades have
put us in a position to offer therapy delaying disease progression, thus delaying nursing
home admission, and there is the promise of true disease-modifying agents in the near
future. There is an important genetic risk for Alzheimer’s disease associated with the E*4
allele of the apolipoprotein gene (APOE*4) (1). With our increasing understanding of
the clinical and pathophysiological characteristics of Alzheimer’s disease, attention is
now focusing on the earliest manifestations of the disease in an effort to identify people
at risk who might benefit from new therapies—including individuals who are cogni-
tively normal. At the same time, new advances are being made in the nonpharmacolog-
ical treatment of Alzheimer’s disease and related
dementias in recognition of the current limita-
tions in more traditional treatment regimens.
Alzheimer’s disease is now seen as a disease
with multiple risk factors. Although many of
them may be causal, the majority are thought to
be risk modifiers in that they can accelerate or
decelerate the time to develop the clinical mani-
festations of the disease, i.e., the dementia itself.
Although there is nothing that we can do about
our genetic makeup, altering other factors may
play an important role in the natural history of
the disease. Two articles in this issue of the Jour-
nal make these points explicitly.
Chen and colleagues analyzed the rate of
change of whole brain volumes as a function of
APOE*4 “load” in cognitively normal subjects. They found that individuals who had two
copies of the E*4 allele had more rapid loss of brain tissue than individuals either with a
single copy or who were E*4 negative. This collaborative study used two different tech-
niques—brain boundary shift integration and iterative principal components analysis.
The analyses were completed at two different laboratories using the same data set of
anatomical magnetic resonance imaging (MRI) scans from 36 cognitively normal sub-
jects; each of these individuals was scanned twice approximately 2 years apart. Brain
boundary shift integration uses the movement (“shift”) of the brain-CSF boundary as
the measure of diffuse atrophy. The change in volume over time is standardized into a
rate of change relative to each subject’s own baseline MRI scan. The iterative principal
components analysis, by contrast, establishes which portions of the brain had a signifi-
cantly greater change in intensity than the typical intensity change within the whole
brain. The total volume of the brain that is determined to have had significantly greater
change is then quantified as volume gain (or relocation) or volume loss (atrophy) as a
rate of change over time.
Both techniques found statistically large and significant associations between
APOE*4 load and the annual rate of whole brain atrophy. Although both techniques
demonstrated a significant difference between the atrophy rates for the E*4 homozy-
gotes and those of the noncarriers, the statistically smaller effects of the heterozygotes
versus the homozygotes were not significant (and would have required 50–80 total cases
to be adequately powered).
“Until such time as 
treatments are available 
that can truly modify or 
prevent Alzheimer’s 
disease, improving and 
extending the period of 
higher quality of life may 
be the most important 
clinical outcome.”
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These findings are even more striking because almost without exception, these indi-
viduals remained cognitively normal throughout the follow-up period and beyond. Fur-
ther follow-up of this important group of at-risk individuals will allow Chen and col-
leagues the opportunity to describe both the whole brain changes as individuals
transition to Alzheimer’s disease and also the regionally specific changes that may serve
as sensitive and specific biomarkers of the trajectory toward Alzheimer’s disease.
As much as genotype plays an important and still immutable role in the natural his-
tory of Alzheimer’s disease, Wilson and colleagues have found evidence that environ-
mental factors can affect the way in which individuals with moderate to severe Alzhei-
mer’s disease adapt to their environment. Specifically, the transition to nursing home
care is made easier if the patient has had prior experience in a day care setting. They ex-
amined the cognitive function of more than 400 Alzheimer’s disease patients over a 4-
year period as the patients made the transition from home to institutional care. Place-
ment in a nursing home resulted in a decrease in performance on measures of cogni-
tion—due in part to the progression of the disease but also, more than likely, to the dis-
ruptive effects of the move on a range of adaptive functions. However, if the patient had
been in a day care setting before admission to the nursing home, then the accelerated
cognitive decline while in the nursing home was essentially eliminated. The effect was
powerful enough to attenuate the association between higher educational attainment
and more rapid decline after nursing home admission.
The authors discussed their findings in the context of the potentially beneficial effects
of nonspecific experience in an institutional setting (i.e., day care) on the adaptation to
the nursing home environment. It may also be the case, as noted by the authors, that in-
dividuals who use day care services—or the families of those patients—differ in impor-
tant ways from those who do not.
However, it is also possible that the day care setting itself may have had a beneficial ef-
fect on cognition and adaptive functions. The day care environment, even those with
limited structured programs, may provide increased social contacts, opportunities for
cognitive stimulation, and physical exercise. Individually these different activities may
have limited efficacy, but in combination they may have beneficial effects.
Cognitive stimulation in the context of a day care setting does have a beneficial effect
on mental status (2). Alzheimer’s disease patients participating in a psychostimulation
program integrated into a day care center had a mean increase in scores on the Mini-
Mental State Examination of 1.13 points over a 24-week observation period (versus a
1.5-point decline in the control group). Although the dementia of the patients in that
study was much less severe than that of the patients evaluated by Wilson and col-
leagues, the main point is the same: maintaining as much contact as possible with the
outside world and exercising the mind and body likely have positive and beneficial ef-
fects on the natural history of Alzheimer’s disease up to and including the time after
nursing home placement.
How might these changes occur? Before the emergence of medications to treat the
symptoms of Alzheimer’s disease, cognitive stimulation was thought to be potentially
beneficial for dementia patients. Although cognitive stimulation does not always ap-
pear efficacious and methodological problems may limit the validity of some studies
(3), certain cognitive domains may benefit from these interventions (4). All of these
findings are in line with the emerging line of studies that demonstrate that Alzheimer’s
disease patients retain a remarkable degree of CNS plasticity and adaptability. Although
many of these mechanisms are observed early in the course of the disease (e.g., refer-
ences 5 and 6), pathological studies conducted in biopsied Alzheimer’s disease patients
with mild/moderate dementia have shown increased synaptic contact size (7).
To date, there is no evidence that therapies targeted at Alzheimer’s disease alter the
time to death (e.g., reference 8), although time to cognitive (9) and noncognitive out-
comes (8) are extended. To the extent that factors such as APOE*4 status affect the un-
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derlying neuropathology, we can imagine that multiple factors expand or compress de-
mentia-free time or time with higher quality of life (see Figure 1). This idea is related
directly to the concept of compression of morbidity (10), which posits the ideal of a
long(er), higher quality life with a relatively short(er) period of terminal decline. In the
present context, illness burden (i.e., the presence of clinical dementia) is reduced by
both pharmacological and nonpharmacological means with an end result of a “com-
pression” of the time of most severe dementia until death.
Environment interactions and their effects on the natural history of Alzheimer’s dis-
ease are important in developing rational treatment management strategies. We cannot
alter our genes (yet), and these confer an additional burden on the CNS and result in
earlier expression of the dementia. However, we can alter our environment, and this ap-
pears to expand the time of higher quality of life (defined as better mental status or time
outside of nursing home care). Until such time as treatments are available that can truly
modify or prevent Alzheimer’s disease, improving and extending the period of higher
quality of life may be the most important clinical outcome. These two studies reported
in the Journal demonstrate the importance of understanding these complex genetic
and environmental factors in modifying the natural history of Alzheimer’s disease.
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FIGURE 1. Effects of Modification of the Natural History of Alzheimer’s Diseasea
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Tarraga.
Typical course of Alzheimer’s 
disease dementia
Modified course of dementia
Improved function
Severe impairment
≤ 1 year
Death
3 to 5 years
Years of clinical disease
Compression of
cognitive morbidity
–
+
852 Am J Psychiatry 164:6, June 2007
EDITORIAL
ajp.psychiatryonline.org
6. Herbster AN, Nichols T, Wiseman MB, Mintun MA, DeKosky ST, Becker JT: Functional connectivity in auditory
verbal short-term memory in Alzheimer’s disease. Neuroimage 1996; 4:67–77
7. DeKosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlations with cog-
nitive severity. Ann Neurol 1990; 27:457–464
8. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST: Cholinesterase inhibitor treatment alters
the natural history of Alzheimer’s disease (abstract). J Neurol Neurosurg Psychiatry 2002; 72:310
9. Lopez OL, Becker JT, Saxton J, Sweet R, Klunk W, DeKosky ST: Alteration of a clinically meaningful outcome
in the natural history of Alzheimer’s disease by cholinesterase inhibition. J Am Geriatr Soc 2005; 53:83–87
10. Fries JF: Aging, natural death, and the compression of morbidity. N Engl J Med 1980; 303:130–135
JAMES T. BECKER, PH.D.
LUIS TARRAGA MESTRE, M.SC.
SCOTT ZIOLKO, B.S.
OSCAR L. LOPEZ, M.D.
Address correspondence and reprint requests to Dr. Becker, Neuropsychology Research Program, Suite 830,
3501 Forbes Ave., Pittsburgh, PA 15213; beckerjt@msx.upmc.edu (e-mail).
Dr. Becker has been a consultant for Grifols S.A. and received an advisory panel payment from Forest. Dr. Lo-
pez has been a consultant for and on the advisory panel for Eisai/Pfizer and Forest and a consultant for Gri-
fols and Servier. The remaining authors report no competing interests.
